If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

Victoza (liraglutide) solution for injection is prescribed to help manage blood sugar and reduce major heart-related risks. Victoza is not safe to use while pregnant and may not be safe to use while ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes medications — also known as GLP-1 and GIP injections — are changing the way we ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), significantly improving access to diabetes treatment. The glucagon-like peptide-1 ...

Approval of the once-daily injection, as an adjunct to diet and exercise, is intended to help with drug shortages and improve patient access. (HealthDay News) — The US Food and Drug Administration has ...

The FDA first approved Victoza in 2010 for Type 2 diabetes, later expanding its use in 2019 as a pediatric, injectable treatment for patients 10 or older. Hikma’s generic includes similar warnings to ...

Liraglutide is indicated for the treatment of insufficiently controlled type 2 diabetes. PITTSBURGH — Generic drug maker ...

Add Yahoo as a preferred source to see more of our stories on Google. Liraglutide, sold under the brand name Victoza for diabetes, is an earlier iteration in the same class of drug as semaglutide, the ...

Biocon Pharma has secured US FDA approval for its generic Liraglutide (gVictoza). (Image: Reuters) Biocon’s shares to remain in focus as its wholly owned subsidiary, Biocon Pharma, has received ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the treatment ...

As concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts to ward off competition against its aging diabetes blockbuster Victoza have been ...